OrbiMed Asia Partners VI closes $1.05B institutional private equity fund
OrbiMed Advisors closed a $1.05B private equity fund for institutional investors under Regulation D exemption 3(c)(7). The fund, incorporated in the Cayman Islands in 2025, reached 72 investors and held its first sale on September 30, 2025.
How this compares
- $1.05B is larger than 99% of the 3,008 private equity / buyout fund launches with a stated size in the last two years; the median is $5.1M.
- Among 1,691 fund launches filed from NY in the same window it is larger than 99%; the NY median is $5M.
- Across 490 private equity / buyout sponsors with more than one launch on EDGAR, the median gap between consecutive funds is 5 months.
- This is the sponsor's 2nd fund launch on EDGAR; the previous one, OrbiMed Asia Partners VI, L.P., was filed 13 months earlier at $850M.
Computed from every Form D fund launch on EDGAR since late 2024, not sampled. Amounts are the stated offering size; indefinite offerings are excluded.
OrbiMed on EDGAR
Earlier and related filings by the same issuer and sponsor. All Orbimed Asia vehicles →
OrbiMed Asia Partners VI, L.P. files a $850M private equity / buyout fund
People on the filing
| N/A OrbiMed Asia GP VI, L.P. | Executive Officer |
| N/A OrbiMed Advisors VI Limited | Executive Officer |
| Carl L. Gordon | Director |
| W. Carter Neild | Director |
| Sunny Sharma | Director |
| David G. Wang | Director |
Signed by W. Carter Neild, Director of the GPLTD.
Placement agents / sales compensation: UBS Switzerland AG; MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED; J.P. Morgan Securities LLC
Why now — by persona
- Fund administrator:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- Fund audit & tax:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
Filing contact
The issuer's phone number and address from the filing are shown to subscribers. See plans.